Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Source: Globenewswire
Dyne Therapeutics Public Offering: Dyne Therapeutics has announced a public offering of 24,242,425 shares of common stock at $8.25 per share, aiming to raise approximately $200 million before expenses, with the offering expected to close around July 2, 2025.
Company Focus and Future Plans: The company specializes in developing therapeutics for genetically driven neuromuscular diseases, including ongoing clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy, while also addressing risks associated with forward-looking statements regarding their future plans.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
